Ticker

Analyst Price Targets — GOSS

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
February 24, 2026 12:45 pmWedbush$1.00$0.42TheFly Wedbush downgrades Gossamer Bio to Neutral, lowers target to $1
February 24, 2026 9:34 amEliana MerleBarclays$0.30$0.42StreetInsider Barclays Downgrades Gossamer Bio Inc. (GOSS) to Underweight
February 24, 2026 1:59 amLeerink Partners$1.00$0.42TheFly Gossamer Bio downgraded to Market Perform from Outperform at Leerink
January 27, 2026 9:24 pmBarclays$9.00$2.64TheFly Gossamer Bio initiated with an Overweight at Barclays
September 10, 2025 8:32 amUBS$9.00$3.11TheFly Gossamer Bio upgraded to Buy from Neutral at UBS
December 8, 2022 6:24 amH.C. Wainwright$5.00$2.16Benzinga HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $5
December 7, 2022 6:57 amBarclays$2.00$2.36Benzinga Barclays Downgrades Gossamer Bio to Equal-Weight, Lowers Price Target to $2
December 7, 2022 3:58 amRaymond James$5.00$2.36Benzinga Raymond James Maintains Outperform on Gossamer Bio, Lowers Price Target to $5
December 6, 2022 5:54 pmDavid HoangSMBC Nikko$3.00$2.36TheFly Gossamer Bio downgraded to Neutral from Outperform at SMBC Nikko
April 26, 2022 8:50 amBarclays$12.00$8.45Benzinga Barclays Maintains Overweight on Gossamer Bio, Lowers Price Target to $12

Latest News for GOSS

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the initial conversion rate for its 7.50% Convertible Senior Secured First…

Business Wire • Jul 1, 2026
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the…

Business Wire • Jun 17, 2026
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the…

Business Wire • Jun 3, 2026
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has extended the early tender date (as extended, the “Extended Early…

Business Wire • Jun 2, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for GOSS.

No House trades found for GOSS.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top